I am proud to announce that we treated our first pediatric patient with the Eclipse XL1 System for intestine lengthening.?The patient was a 2 year-old-boy struggling with Short Bowel Syndrome (SBS). We are hopeful that this exciting technology will help him and many more patients like him in the future.?A huge CONGRATULATIONS goes out to Dr James Dunn (inventor) on this major accomplishment. Here are a few words from Dr Dunn on the case... (Note: This was an expanded use of the Eclipse XL1, an investigational medical device currently being studied to evaluate safety and effectiveness.)
Eclipse Regenesis
医疗设备
Menlo Park，California 331 位关注者
The First Tissue Regeneration Therapy For Short Bowel Syndrome (SBS).
关于我们
The first tissue regeneration therapy for Short Bowel Syndrome (SBS). SBS is a devastating condition where the small intestine is too short to absorb sufficient nutrients to sustain a patient. It results from the surgical removal of a large portion of the small intestine due to a congenital or acquired defect. The Eclipse XL1 therapy is designed to grow 2-3x longer, healthy intestine within 2-3 weeks using an entirely mechanical, repeatable approach. The new tissue has been shown to absorb nutrients and function the same as, or better than, healthy intestinal tissue. The Eclipse XL 1 device is an investigational product and limited by Federal law to investigational use. It is not currently available for commercial sale in the U.S. or any other region. Eclipse Regenesis and Eclipse XL1 are registered trademarks of Eclipse Regenesis, Inc.
- 网站
-
https://www.eclipseregenesis.com
Eclipse Regenesis的外部链接
- 所属行业
- 医疗设备
- 规模
- 2-10 人
- 总部
- Menlo Park，California
- 类型
- 私人持股
- 创立
- 2017
- 领域
- short bowel syndrome、medical device和tissue regeneration therapy
地点
-
主要
获取路线
1440 O'Brien Drive
Suite D
US，California，Menlo Park，94025
Eclipse Regenesis员工
动态
-
Administering grant programs and providing mentorship to selected projects is one of the principal means by which we enable innovations to “translate” from the university into commercial development. ‘Clinical-grade Springs for Intestinal Lengthening’ was one of our Coulter program grantees in 2017 and 2018. It’s wonderful to see the evolution of this project into the company 'Eclipse Regenesis' and the impact it’s made on its first pediatric patient. Read the story: https://lnkd.in/g8wXC_QD? CC: James Dunn, Tom Krummel, Eclipse Regenesis, Fogarty Innovation, Impact1 at Stanford Biodesign.
-
“I just thought, will this kid ever be able to eat normally? I love food—we all love food. And thinking that he wouldn’t was just the saddest thing.” —David DeLeon, Diego's dad. Learn about the compassionate use of an investigative device from Eclipse Regenesis to help a little boy with short bowel syndrome: https://lnkd.in/g8wXC_QD
-
-
Dr. James Dunn is a co-founder of Fogarty company-in-development Eclipse Regenesis, which is working on the first tissue regeneration therapy for short bowel syndrome (SBS). Through FDA compassionate use, the investigational Eclipse device was recently used to help a little boy with SBS get off intravenous nutrition and eat food normally. Look for the story in our December newsletter, coming out next week!
*Be passionate about your work and be persistent in your pursuit* Our Chief of Pediatric Surgery Dr. James Dunn says he encourages “all the faculty to develop specialty interests and to… accomplish something that's audacious.” Learn about his passion project: a spring that uses distraction enterogenesis to lengthen the intestines of patients with small bowel syndrome. https://lnkd.in/gVwqWtFB